GLP-1 analogs, such as Liraglutide and Exendin-4, unlike endogenously produced GLP-1, are not rapidly degraded by Dipeptidyl peptidase-4 (DPP-4) and, therefore, can induce sustained therapeutic actions, that otherwise would not be possible due to the exceedingly short half-life of endogenous GLP-1 in circulation
Bicep tendonitis is an inflammation or irritation of the long head of the biceps tendon
Potential Downsides of Microdosing Reduced Efficacy One of the primary concerns with microdosing GLP-1 drugs is that lower doses may not provide the desired therapeutic effects
In the Phase 3 TRIUMPH-1 trial in adults with obesity (without type 2 diabetes), the highest studied dose was associated with an average weight loss of about 28.3% at 80 weeks roughly 70 pounds reaching about 30.3% at 104 weeks, and about 45% of participants lost at least 30% of their body weight
This rapid improvement in energy is particularly important for individuals whose daily lives are affected by persistent tiredness and weakness